What question did this study set out to answer?

To evaluate the clinical validity and diagnostic utility of platelet consumption, survival, and turnover assays across diverse arterial and venous thromboembolic disorders.

January 1, 1982Seminars in Thrombosis and Hemostasis

Platelet Consumption in Cardiovascular Disease

View Full Paper

Ask AI

Bookmark

Why the study?

Do tests of platelet release and survival accurately detect platelet activation and consumption in patients with cardiovascular disease?

Population

Patients with cardiovascular disease, including thromboembolic disorders, arteriosclerosis, venous…

Design

Review

Authors

ATAlexander G.G. TurpieVascular Medicine ABA. De BoerKU Leuven EGEdward GentonUniversity of Colorado Boulder

Discussion

Member takes

Implication

Limited sensitivity precludes routine clinical use in most cardiovascular diseases; leaves open targeted validation in venous thromboembolism and prosthetic valves.

Key Points

To evaluate the clinical validity and diagnostic utility of platelet consumption, survival, and turnover assays across diverse arterial and venous thromboembolic disorders.
Reviewed diagnostic performance and sensitivity of in vivo platelet release, platelet survival time, and turnover assays across various cardiovascular and thromboembolic conditions.
Assessed assay consistency in conditions affecting large vessels, prosthetic heart valves, active venous thromboembolism, and localized arterial diseases.
Platelet consumption and shortened platelet survival time consistently present in acute and recurrent venous thromboembolism, older prosthetic cardiac valves, and large-vessel arteriosclerosis.
Data remain inconclusive in coronary artery disease, cerebrovascular disease, and peripheral vascular disease due to insufficient test sensitivity for minor platelet activation.
Current platelet survival and consumption assays demonstrate limited utility for guiding routine clinical management in patients with thromboembolic disorders.

Structured PICO

Do tests of platelet release and survival accurately detect platelet activation and consumption in patients with cardiovascular disease?

Population

Patients with cardiovascular disease, including thromboembolic disorders, arteriosclerosis, venous thromboembolism, cardiac valve replacement, coronary artery disease, cerebrovascular disease, and peripheral vascular disease

Intervention

Tests of in vivo platelet release, platelet survival, and platelet turnover

Outcome

Detection of platelet activation and consumptionsurrogate

Tests of platelet release and survival have limited clinical utility in managing most cardiovascular diseases due to insufficient sensitivity, though they show consistent abnormalities in specific conditions like venous thromboembolism and older prosthetic valves.

Limitations

Tests may lack sensitivity and specificity to detect minor changes in platelet activation
Limited value in the clinical management of patients with thromboembolic disorders

Cite This Study

Turpie et al. (1982) studied this question.

synapsesocial.com/papers/6a91a65fbba48a71aec7322f https://doi.org/10.1055/s-2007-1005050

Topics

Valvular heart disease

View Full Paper

Ask AI

Bookmark

Implication

Limited sensitivity precludes routine clinical use in most cardiovascular diseases; leaves open targeted validation in venous thromboembolism and prosthetic valves.